Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: Potential role of vascular endothelial dysfunction

Daisuke Sueta,Koichi Suyama,Aiko Sueta,Noriaki Tabata,Takayoshi Yamashita,Mai Tomiguchi,Takashi Takeshita,Mutsuko Yamamoto-Ibusuki,Eiichiro Yamamoto,Yasuhiro Izumiya,Koichi Kaikita,Yutaka Yamamoto,Seiji Hokimoto,Hirotaka Iwase,Kenichi Tsujita

Atherosclerosis（2017）

引用 34|浏览9

暂无评分

摘要

•Lenvatinib is effective for differentiated thyroid carcinoma (DCT).•Lenvatinib is an oral multi-kinase inhibitor, which inhibits vascular endothelial growth factor (VEGF) pathway.•Lenvatinib demonstrates hypertension in very high ratio in DTC patients.•Lenvatinib administration revealed vascular endothelial dysfunction in human.•The present study may thus provide a breakthrough for therapeutic interventions.

查看译文

关键词

Lenvatinib,Vascular endothelial growth factor,Endothelial dysfunction

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要